Financial Data and Key Metrics Changes - The company reported an adjusted EBITDA of BRL 2.2 billion for the quarter, reflecting a 15% increase compared to the previous year [14][21] - Total investments for the first half of the year reached BRL 2.7 billion, with a full-year investment plan of BRL 2.8 billion [4][11] - The net debt to adjusted EBITDA ratio improved to 1.59, indicating a strong leverage position [18] Business Line Data and Key Metrics Changes - The distribution segment saw significant investments, with nine substations energized and over 2,600 kilometers of low and medium voltage networks constructed [12] - The energy market for semi-distribution experienced a 3.3% drop, attributed to the migration of industrial clients to the free market [21][22] - The gas segment, GASMIG, reported improved EBITDA and net profit due to efficient cost management [29] Market Data and Key Metrics Changes - The company noted a gross effect of BRL 76 million related to price differences in energy submarkets, which is expected to normalize in the future [6][17] - The distributed generation market showed a significant growth of around 20% compared to the previous year [22] Company Strategy and Development Direction - The company is focused on a BRL 59 billion investment plan from 2019 to 2029, primarily targeting distribution to meet unmet load and support distributed generation [36][42] - Future investments will also aim to enhance resilience and automation in operations, responding to regulatory requests [38] Management Comments on Operating Environment and Future Outlook - Management expressed optimism about the second half of the year, anticipating positive scenarios regarding tariff adjustments and energy market conditions [5][7] - The company is closely monitoring regulatory changes and their potential impacts on profitability, especially concerning tariff reviews and pension fund expenses [50][54] Other Important Information - The company successfully participated in the GSF auction, securing extensions for three power plants, which is expected to add value in the long term [8][28] - The Supreme Court's recent ruling on tax deductions is viewed positively, although the final impacts are still being assessed [44][45] Q&A Session Summary Question: Comments on capital allocation and future focus - Management highlighted a strategic focus on distribution investments to address unmet load and support distributed generation, with a strict rule to invest only in Minas Gerais [34][36][42] Question: Impact of recent Supreme Court ruling on taxes - Management acknowledged the positive implications of the ruling but emphasized the need to wait for final details to assess the full impact [44][45] Question: Rationale behind increasing short positions for 2027-2028 - Management clarified that the increase in short positions was a result of market conditions and ongoing efforts to close positions and reduce exposure [47][48] Question: Regulatory environment's effect on profitability and pension fund expenses - Management stated that efficiency improvements are a priority, and discussions on tariff adjustments are ongoing, with a focus on reducing costs in pension plans [50][51][54]

Financial Data and Key Metrics Changes - The company reported an adjusted EBITDA of BRL 2.2 billion for the quarter, reflecting a 15% increase compared to the previous year [14][21] - Total investments for the first half of the year reached BRL 2.7 billion, with a full-year investment plan of BRL 2.8 billion [4][11] - The net debt to adjusted EBITDA ratio improved to 1.59, indicating a strong leverage position [18] Business Line Data and Key Metrics Changes - The distribution segment saw significant investments, with nine substations energized and over 2,600 kilometers of low and medium voltage networks constructed [12] - The energy market for semi-distribution experienced a drop of 3.3% due to the migration of industrial clients to the free market [21] - The company reported a gross effect of BRL 76 million related to price differences in energy submarkets [6][17] Market Data and Key Metrics Changes - The company noted a significant growth of around 20% in distributed generation compared to the previous year [22] - The trading sector faced a negative impact of BRL 76 million due to differences among energy submarkets [6][21] Company Strategy and Development Direction - The company is focused on a BRL 59 billion investment plan from 2019 to 2029, primarily targeting distribution to meet unmet load and support distributed generation [36][42] - Future investments will also aim to enhance resilience and automation in service delivery [38] Management Comments on Operating Environment and Future Outlook - Management expressed optimism about the second half of the year, anticipating positive scenarios regarding tariff adjustments and energy trading [6][7] - The company is closely monitoring regulatory changes and their potential impacts on profitability, especially concerning tariff reviews and pension fund expenses [50][55] Other Important Information - The company successfully participated in a GSF auction, securing extensions for three power plants, which is expected to add value [8][28] - The company is actively working on reducing operational expenses while improving service quality through technology and efficiency initiatives [51][54] Q&A Session Questions and Answers Question: Comments on capital allocation and future focus for transmission auctions - Management highlighted that the bulk of investments will be in distribution to address unmet load and support distributed generation, with a focus on regulatory sectors [36][39] Question: Impact of recent Supreme Court ruling on PIS and ICMS - Management noted that the ruling allows for the deduction of taxes and honoraries, which is positive, but the final ruling's impact is still uncertain [44][45] Question: Rationale behind increasing short position for 2027-2028 - Management clarified that the increase in short position was due to market conditions and the need to close existing positions, with a focus on reducing exposure moving forward [47][48] Question: Regulatory changes affecting profitability and pension plan expenses - Management emphasized the importance of efficiency and technology in improving service quality and managing costs, with ongoing negotiations regarding pension funds [50][55]

Financial Data and Key Metrics Changes - The company has transitioned to a Phase III company, indicating significant progress in its clinical development [21] - CYB3 demonstrated a 71% remission rate in patients with uncontrolled depression after just two doses in a Phase II study, showcasing a substantial efficacy advantage over standard treatments [24] Business Line Data and Key Metrics Changes - The company is advancing its lead program CYB3, which is in the final stage of development for treating major depressive disorder (MDD) [22] - CYB4, a program for generalized anxiety disorder (GAD), is in a Phase II proof of concept study, with enrollment expected to complete in August 2025 [29] Market Data and Key Metrics Changes - The commercial success of esketamine, with sales of $366 million in the US and $414 million worldwide, reflects a growing market for innovative mental health treatments [32] - The company is witnessing a supportive political and regulatory environment, which is expected to expedite regulatory pathways for psychedelic therapies [31] Company Strategy and Development Direction - The company is focused on executing its clinical programs while preparing for regulatory submissions and commercial manufacturing readiness [28] - Strategic collaborations with Thermo Fisher Scientific and AusMind are aimed at enhancing manufacturing capabilities and supporting commercial preparation [27] Management's Comments on Operating Environment and Future Outlook - The management expressed optimism about the regulatory environment, citing bipartisan support and positive signals from US agencies [31] - The company is well-capitalized and positioned for multiple near-term inflection points in its clinical programs, reinforcing its leadership in the sector [34] Other Important Information - The company has significantly expanded its intellectual property portfolio, now comprising over 100 granted patents and more than 250 pending applications [30] - The EMBRACE study will enroll approximately 330 participants across 60 clinical sites in the US, Europe, and Australia, indicating a robust international research base [26] Q&A Session Summary Question: What is the current status of the clinical programs? - The company is currently in Phase III for CYB3 and expects to have top-line readout in 2026, with ongoing enrollment in the EMBRACE study [28][34] Question: How does the company view the regulatory environment? - Management highlighted a positive shift in the regulatory landscape, with increased support from government officials and agencies, which is expected to benefit the entire sector [31]

Financial Data and Key Metrics Changes - The company reported a quorum present for the meeting, indicating active shareholder participation [9] - The proposals for the election of directors and the appointment of the independent auditor were approved by a majority of votes cast [14] Business Line Data and Key Metrics Changes - No specific business line data or key metrics were discussed during the meeting Market Data and Key Metrics Changes - No specific market data or key metrics were discussed during the meeting Company Strategy and Development Direction and Industry Competition - The company proposed a reverse stock split with a ratio of not less than 1.45 and not greater than 1.45, which may indicate a strategy to enhance share price and market perception [11] Management Comments on Operating Environment and Future Outlook - Management did not provide specific comments on the operating environment or future outlook during this meeting Other Important Information - The meeting included formal steps taken for the election of directors and the appointment of auditors, ensuring compliance with regulatory requirements [3][5] - The company emphasized that any forward-looking statements made during the meeting are subject to risks and uncertainties [5] Q&A Session Summary - No Q&A session was conducted during this meeting, as the focus was on formal proposals and voting outcomes

Financial Data and Key Metrics Changes - The company's GMV for Q2 was $36.4 billion, with a first half GMV of $70.6 billion, reflecting a 45% year-over-year increase [15] - Q2 revenue reached a record $81.1 million, up 3% year-over-year, while first half revenue was $163.4 million, up 5% year-over-year [15] - Non-GAAP gross profit margin for 2025 was approximately 50%, down from 53% in the prior year [19] - Positive adjusted EBITDA of $2.1 million in Q2 and $3.5 million for the first half of 2025, marking the seventh consecutive quarter of positive adjusted EBITDA [21] Business Line Data and Key Metrics Changes - The two largest categories, tickets and travel, and fashion and luxury, grew 1510% year-over-year, driven by strong new business wins and upsell activity [15] - The home category saw a year-over-year decline of 74%, while the money transfer and payments category achieved approximately 90% year-over-year growth in Q2 [17] - Fashion and luxury category growth was partially offset by same-store sales pressure, particularly in high-end fashion and sneakers [16] Market Data and Key Metrics Changes - The United States market declined 11% year-over-year, primarily due to the contraction in the home category, while APAC grew approximately 40% year-over-year [18] - Other Americas (Canada and Latin America) grew approximately 16% year-over-year, and EMEA grew approximately 23% year-over-year, with strong performance in fashion and luxury, tickets and travel, and money transfer and payments [18] Company Strategy and Development Direction - The company aims to gain market share in existing categories and geographies while expanding into new verticals to diversify its merchant base [7] - A partnership with Human Security was announced to enhance fraud prevention capabilities in the evolving landscape of AI commerce [10] - The board authorized an additional $75 million share repurchase program, reflecting confidence in the company's long-term trajectory [13] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the solid first half performance and the potential for improvement in the second half, supported by a robust new business pipeline [6] - The company anticipates delivering an annual non-GAAP gross profit margin of approximately 52% for 2025, with expectations for higher margins in the second half [20] - Management highlighted the increasing complexity of fraud and the need for advanced solutions, positioning the company as a leader in the market [89] Other Important Information - The company ended Q2 with $339 million in cash, deposits, and investments, maintaining a debt-free balance sheet [22] - Quarterly free cash flows were $5.3 million, up from $4.1 million in the prior year, with an expectation of approximately $30 million of positive free cash flow for 2025 [22] Q&A Session Summary Question: Expectations for the second half of the year and same-store sales in fashion and luxury - Management is optimistic about the sales pipeline and expects win rates to be similar to historical levels, but same-store sales in fashion and luxury may be flat or down [27][30] Question: Impact of AgenTek Commerce on pipeline conversations - The evolving space of AgenTek Commerce is generating new conversations and budget opportunities as merchants seek to address AI-related challenges [32][34] Question: Trends in performance by vertical and same-store sales commentary - Travel and payments performed well, while ticket sales showed some softness, particularly in June, with expectations for a challenging comparison to the previous year's strong performance [39][41] Question: Management of operating expenses - Operating expenses were managed well, with expectations for similar levels in the second half of the year [43][45] Question: Adoption trends for adaptive checkout and its impact on new logos - Adaptive checkout has seen double-digit percentage adoption, contributing positively to the overall value proposition [47][49] Question: Proportion of fraud from large coordinated attacks - There has been an increase in professional, coordinated fraud attacks, primarily through remote desktop hacking and data breaches [72] Question: Renewal rates and upsell strategies - The company achieved a 100% renewal success rate and continues to focus on creating unmatched value for merchants [80][81]

Financial Data and Key Metrics Changes - The company reported revenue of $7.4 million for Q2 2025, marking a 31% increase year over year [31] - Adjusted EBITDA for Q2 was negative $2.5 million, an improvement from negative $3.1 million in Q2 2024 [32] - Gross margin on IFRS basis was approximately 67%, up from 65% in Q2 last year [32] Business Line Data and Key Metrics Changes - Platform revenue reached $2.5 million, up 23% year over year, marking the fourth consecutive quarter of growth exceeding 20% [31] - Solutions revenue increased by 36% year over year to $4.9 million, reflecting proactive expansion of product capabilities [31][24] Market Data and Key Metrics Changes - The air cargo market saw a 3% increase in volumes compared to Q2 last year, despite challenges from tariff changes [14] - Ocean freight rates rose 43% from Q1 but were still 11% lower than last year, indicating capacity growth and potential overcapacity [15] Company Strategy and Development Direction - The company aims to digitalize international freight, positioning itself as a leading global freight platform [10][11] - Strategic expansion includes adding new carriers, with a total of 75 carriers now on the platform, enhancing coverage on critical routes [19] - The company is focused on increasing liquidity in ocean capacity and modernizing IT among ocean carriers [21][23] Management's Comments on Operating Environment and Future Outlook - Management noted that while tariffs have created some headwinds, the overall impact is minor compared to the trend of digitalization driving long-term growth [17] - The company remains on track to achieve breakeven adjusted EBITDA by the end of 2026, with confidence in sustaining growth rates [33][75] Other Important Information - The company has a strong balance sheet with $34 million in cash and cash equivalents [33] - The company plans to participate in several investor events, including the H. C. Wainwright Annual Investment Conference in September [4] Q&A Session Summary Question: Why did the company raise full year GBV guidance but keep revenue largely unchanged? - Management indicated that the mix of transactions affects revenue, with some lower take rate transactions growing faster [38][39] Question: How is the ShipStar position helping drive solutions revenue? - The integration of ShipStar has enhanced the product portfolio, enabling cross-sell opportunities and improving data offerings [41][42] Question: What is driving the pressure for modernization in the ocean freight sector? - The need for digital connections is being driven by customer demand for efficiency, moving away from traditional methods like Excel sheets [52] Question: Are there any strategic changes or new growth areas being evaluated? - Management is continuously reviewing resource allocation but does not expect any major changes at this time [60][61] Question: How much did FX fluctuations impact Q2 profitability? - FX fluctuations significantly affected adjusted EBITDA, but the company has managed to hedge nearly 100% of its exposure [62][64] Question: How does the company expect to achieve breakeven by the end of next year? - Management is confident in reaching breakeven with current growth trends and operational expense management [75][76]

Financial Data and Key Metrics Changes - The company reported a revenue of RMB950 million for the first half of 2025, with over RMB300 million coming from commercialized drugs, marking a significant achievement in its first year of commercialization [50][51] - Gross profit was RMB660 million, comparable to the previous year, while the net loss for the first half was RMB145 million, with an adjusted loss of RMB69 million after one-off budget adjustments [52][53] Business Line Data and Key Metrics Changes - The company has three main products ready for the market, with significant progress in approvals and commercialization efforts [12][21] - The commercialization team has expanded to nearly 400 personnel to support the increasing number of products [12] Market Data and Key Metrics Changes - The company has covered over 30 provinces, 300 cities, and over 1,000 hospitals across China, with partnerships established with over 400 pharmacies [28][32] - The company is actively working towards gaining medical insurance coverage for its products, which is expected to enhance market access [33][34] Company Strategy and Development Direction - The company aims to advance differentiated pipelines targeting significant medical needs, optimizing payload linker strategies, and exploring applications in non-oncology areas [26] - The focus is on expanding global partnerships and strengthening strategic collaborations to maximize the value of its pipelines [26] Management Comments on Operating Environment and Future Outlook - Management expressed optimism about the future income from sales revenue, anticipating continued cash flow generation from both R&D partnerships and commercialized drugs [51] - The company is preparing for the implementation of new medical insurance policies, which could significantly impact product sales strategies [97][100] Other Important Information - The company completed a follow-on financing of US$250 million and is included in several global equity indexes, enhancing its financial stability [25] - The company is involved in ongoing litigation regarding IP disputes with several founders, which has been accepted for review by the Sichuan Provincial High Court [101] Q&A Session Summary Question: What is the breakdown of sales revenue for breast cancer and lung cancer? - Lung cancer is the biggest contributor to sales revenue, consistent with patient numbers and indications. The sales expenses are expected to decrease once products are included in medical insurance coverage [62][63] Question: What is the focus for R&D going into the next stage? - The focus is on developing differentiated products targeting clinical demands, with an emphasis on bispecific targets and new payload strategies [68][70] Question: Can you provide guidelines on the sales trend for Q3? - The company expects quarter-over-quarter growth, with significant contributions anticipated from lung cancer indications [72] Question: What is the rationale behind the clinical trial design for PD L1 positive and negative patients? - The company is focusing on first-line treatment for wild-type non-small cell lung cancer, with ongoing projects in development [88] Question: How is the company planning to navigate the new medical insurance policy? - The company is prioritizing entry into the medical insurance catalog and is actively preparing to comply with the new policy [97][98]

Financial Data and Key Metrics Changes - Total revenue for Q2 2025 was $155.6 million, up 122% sequentially from Q1 and up 57% year over year [8][20] - Gross profit was $12.8 million, with an adjusted EBITDA of $17.3 million, showing significant improvement from Q1 [8][27] - Self mining revenue reached $59.3 million, a 42.5% increase year over year and a 59.4% increase sequentially [21] - Total operating expenses were $42.3 million, up from $26.1 million in Q2 2024, primarily due to R&D costs [25] Business Line Data and Key Metrics Changes - Self mining hash rate increased by 103.3% year over year and 45.5% sequentially, contributing to revenue growth [21] - Sales revenue from SealMiner ASICs was $69.5 million, compared to $0 in Q2 2024 [21] - Cloud Hash Rate revenue declined to $0, down from $12.2 million in Q2 2024, due to the expiration of long-term contracts [22] Market Data and Key Metrics Changes - The average operating hash rate increased by 46% to 14.2 exahash in Q2 from 9.7 exahash in Q1 [8] - The self mining hash rate further grew to 22.3 exahash as of July 2025, representing a 162% increase from the beginning of the year [9] Company Strategy and Development Direction - The company is focused on a vertically integrated and technology-driven growth strategy, investing in chip design, supply chain, and manufacturing [9][10] - Plans to achieve a self mining hash rate of 40 exahash by October 2025, with expectations to exceed this target by year-end [10][18] - The company is also developing the CLO4 chip, targeting breakthrough efficiency for Bitcoin mining and other high-performance applications [13][14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, citing strong momentum and a solid foundation for growth [9][11] - The company anticipates record results on a run rate basis by the end of the year, setting a strong foundation for 2026 and beyond [11][19] - Management highlighted the importance of energy efficiency and performance leadership in the competitive landscape [11][12] Other Important Information - The company has energized 361 MW of data center capacity for self mining as of July 2025, with plans to increase total available power capacity to nearly 1.6 GW [15][16] - The company is in advanced negotiations for a development partner for its HPC AI initiative in Clarington, Ohio [17][18] Q&A Session Summary Question: What is the risk around construction at the Clarington site? - Management indicated that capital requirements would be minimal and provided through the partner, with construction loans on top [34] Question: How is the demand for ASIC production evolving? - Management noted increased demand due to rising hash prices and Bitcoin prices, contributing to a stronger market [36] Question: What is the current status of the HPC initiative? - The focus is on a build-to-suit approach, with flexibility depending on the final customer for the site [41] Question: What is the balance between self mining and external sales for SealMiners? - The company prioritizes internal use for self mining due to high margins, with a gradual transition to external sales as internal capacity fills up [52] Question: What is the outlook for ASIC prices based on current market dynamics? - Management stated that pricing for the A3 chip will be competitive, with significant efficiency advantages [48] Question: What is the customer composition for SealMiner sales? - The sales have been a mix of both public and private miners, with a focus on distributing units for market feedback [109]

Financial Data and Key Metrics Changes - The company reported a revenue of RMB 950 million for the first half of 2025, with over RMB 300 million coming from commercialized drugs, marking a significant achievement in its first year of commercialization [52][53]. - The gross profit was RMB 660 million, comparable to the previous year, while the net loss for the first half was RMB 145 million, with an adjusted loss of RMB 69 million after one-off budget adjustments [54][55]. - Cash and financial assets totaled RMB 4.5 billion, indicating a healthy financial status to support upcoming R&D and innovation [58]. Business Line Data and Key Metrics Changes - The company has three main products ready for the market, with significant progress in commercialization, covering over 30 provinces and 300 cities, and engaging over 10,000 doctors [32][34]. - The commercialization team has expanded to nearly 400 personnel to support the increasing number of products ready for market [14][15]. Market Data and Key Metrics Changes - The company has successfully partnered with over 400 pharmacies across China, enhancing its market access and professional services [32][34]. - The company is actively pursuing medical insurance coverage for its products, with seven provinces already covered under specific affordable care programs [36][37]. Company Strategy and Development Direction - The company aims to advance differentiated pipelines targeting significant medical needs, optimizing payload linker strategies, and exploring applications in non-oncology areas [30]. - The focus is on developing ADCs and small molecules, with an emphasis on bi-specific targets and innovative payloads to replace traditional chemotherapy [70][72]. Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future income from sales revenue, anticipating continued cash flow generation from both R&D partnerships and commercialized drugs [53]. - The company is preparing for the implementation of new medical insurance policies, which are expected to enhance market access and sales volume [100][101]. Other Important Information - The company has completed a follow-on financing of USD 250 million and is included in major global equity indexes, enhancing its market presence [29]. - The company has made significant advancements in clinical trials, with multiple pivotal trials initiated both domestically and globally [25][26]. Q&A Session Summary Question: What is the breakdown of sales revenue for breast cancer and lung cancer? - Lung cancer is the biggest contributor to sales revenue, consistent with patient numbers and indications. The sales expenses are expected to decrease once products are included in the national medical insurance catalog [60][64]. Question: What is the focus for R&D going into the next stage? - The focus is on developing differentiated products targeting clinical demands, with an emphasis on bi-specific targets and innovative payloads [70][72]. Question: Can you provide guidelines on the sales trend for Q3? - The company has recorded quarter-over-quarter growth of several dozen percentage points, indicating a positive sales trend [76]. Question: What is the rationale behind the clinical trial design for PD L1 positive and negative patients? - The company is focusing on developing effective treatments for both PD L1 positive and negative patients, with ongoing trials to assess efficacy [91]. Question: How does the company plan to navigate the new medical insurance policies? - The company is prioritizing entry into the medical insurance catalog and is actively preparing to comply with new policies to enhance market access [100][101].

Financial Data and Key Metrics Changes - Total revenue for Q2 2025 was $155.6 million, up 122% sequentially from Q1 and up 57% year over year [6][18] - Gross profit was $12.8 million, with adjusted EBITDA at $17.3 million, showing significant improvement from Q1 [6][24] - Self mining revenue reached $59.3 million, a 42.5% increase year over year and a 59.4% increase sequentially [19] - Adjusted profit was negative $24.4 million, compared to positive $3.2 million in Q2 2024 [24] Business Line Data and Key Metrics Changes - Self mining hash rate increased by 103.3% year over year and 45.5% sequentially, contributing to revenue growth [19] - SealMiner sales revenue was $69.5 million, compared to $0 in Q2 2024 and $4.1 million in Q1 2025 [19] - Cloud Hash Rate revenue declined to $0 from $12.2 million in Q2 2024 due to the expiration of long-term contracts [20] Market Data and Key Metrics Changes - The average operating hash rate increased by 46% to 14.2 exahash in Q2 from 9.7 exahash in Q1 [6] - As of July 2025, self mining hash rate further grew to 22.3 exahash, representing a 162% increase from the beginning of the year [7] Company Strategy and Development Direction - The company is focused on a vertically integrated and technology-driven growth strategy, investing in chip design, supply chain, and manufacturing [7][10] - Plans to achieve a self mining hash rate of 40 exahash by October 2025, with expectations to exceed this target by year-end [9][16] - The company is developing the CLO4 chip with two independent designs to ensure success and improve energy efficiency [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, citing strong momentum and a positive outlook for the remainder of 2025 and beyond [7][17] - The company anticipates record results on a run rate basis by the end of the year, setting a strong foundation for 2026 [10][17] Other Important Information - The company has energized 361 MW of data center capacity for self mining, with plans to increase total available power capacity to nearly 1.6 GW [14][15] - The company ended the quarter with $299.8 million in cash and cash equivalents, indicating a strong financial position [27][28] Q&A Session Summary Question: What is the risk around construction at the Clarington site? - Management indicated that capital requirements would be minimal and provided through a partner, with construction loans on top [33] Question: How is the pricing for SealMiner sales? - Pricing remained consistent with the previous quarter, with increased demand due to rising Bitcoin prices [35][85] Question: What is the current status of the HPC initiative in Clarington? - The focus is on a build-to-suit approach, with flexibility depending on the final customer [40] Question: What is the demand environment for ASICs? - Demand has remained strong, with no signs of decline, and the market has picked up significantly [71] Question: How will the company balance self mining versus external sales of SealMiners? - The company prioritizes internal use due to high margins but plans to transition to external sales as internal capacity fills up [51]